Loading ETF profile…
This exchange-traded fund (ETF) endeavors to match the capital appreciation and income generation of the LifeSci Biotechnology Clinical Trials Index, disregarding fees and expenses. The underlying index focuses on tracking the financial progress of a carefully chosen group of biotechnology firms engaged in clinical trials. It is important to note that, as of February 27, the fund's official name transitioned from Virtus LifeSci Biotech Clinical Trials ETF to Virtus Biotech Clinical Trials ETF.
| Symbol | Name | Weight | Market Value |
|---|---|---|---|
| SLS | SELLAS Life Sciences Group Inc | 1.23% | $613.29K |
| DFTX | Definium Therapeutics Inc | 1.17% | $584.57K |
| RGNX | REGENXBIO Inc | 1.11% | $552.08K |
| QURE | uniQure NV | 1.07% | $534.23K |
| MNPR | Monopar Therapeutics Inc | 0.99% | $491.71K |
| ABCL | AbCellera Biologics Inc | 0.97% | $481.64K |
| MBX | MBX Biosciences Inc | 0.95% | $471.35K |
| APGE | Apogee Therapeutics Inc | 0.94% | $466.65K |
| FDMT | 4D Molecular Therapeutics Inc | 0.91% | $453.36K |
| JBIO | Jade Biosciences Inc | 0.90% | $447.97K |
| PVLA | Palvella Therapeutics Inc | 0.89% | $442.22K |
| NRIX | Nurix Therapeutics Inc | 0.88% | $437.34K |
| BIOA | BioAge Labs Inc | 0.86% | $429.86K |
| VKTX | Viking Therapeutics Inc | 0.86% | $427.47K |
| LXRX | Lexicon Pharmaceuticals Inc | 0.86% | $427.36K |
| AKTS | Aktis Oncology Inc | 0.86% | $426.75K |
| NTLA | Intellia Therapeutics Inc | 0.86% | $426.31K |
| ATAI | AtaiBeckley Inc | 0.85% | $424.98K |
| GENB | Generate Biomedicines Inc | 0.85% | $424.54K |
| BCAX | Bicara Therapeutics Inc | 0.84% | $420.44K |
| GHRS | GH Research PLC | 0.84% | $419.26K |
| CGEM | Cullinan Therapeutics Inc | 0.84% | $417.89K |
| PRME | Prime Medicine Inc | 0.84% | $416.65K |
| RLAY | Relay Therapeutics Inc | 0.83% | $414.28K |
| SLDB | Solid Biosciences Inc | 0.83% | $412.24K |